Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus

Chang L-Y, Yang Y-L, Shyu M-K, Hwa H-L, Hsieh F-J. Strategy for breast cancer screening in Taiwan: obstetrician-gynecologists should actively participate in breast cancer screening. J Med Ultrasound. 2012;20(1):1–7. https://doi.org/10.1016/j.jmu.2012.01.001 .

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262 .

Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002–2012. J Formos Med Assoc. 2016;115(12):1076–88. https://doi.org/10.1016/j.jfma.2015.10.011 .

America Cancer Society. Breast cancer facts and figures 2013–2014. Atlanta: American Cancer Society, Inc.; 2013.

Al-Lawati JA. Diabetes mellitus: a local and global public health emergency! Oman Med J. 2017;32(3):177–9. https://doi.org/10.5001/omj.2017.34 .

Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep. 2013;13(6):805–13. https://doi.org/10.1007/s11892-013-0425-5 .

Roglic G. WHO Global report on diabetes: a summary. Int J Noncommun Dis. 2016;1(1):3–8.

Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6(2):103–11. https://doi.org/10.1016/S1470-2045(05)01736-5 .

Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85. https://doi.org/10.2337/dc10-0666 .

Gold HT, Makarem N, Nicholson JM, Parekh N. Treatment and outcomes in diabetic breast cancer patients. Breast Cancer Res Treat. 2014;143(3):551–70. https://doi.org/10.1007/s10549-014-2833-x .

He DE, Bai JW, Liu J, Du CW, Huang WH, Zhang GJ. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Mol Clin Oncol. 2015;3(3):607–12. https://doi.org/10.3892/mco.2015.522 .

Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat. 2010;122(3):859–65. https://doi.org/10.1007/s10549-010-0732-3 .

Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(49):e5602. https://doi.org/10.1097/MD.0000000000005602 .

Zhou Y, Zhang X, Gu C, Xia J. Influence of diabetes mellitus on mortality in breast cancer patients. ANZ J Surg. 2015;85(12):972–8. https://doi.org/10.1111/ans.12877 .

Rohlfing CL, Little RR, Wiedmeyer HM, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care. 2000;23(2):187–91. https://doi.org/10.2337/diacare.23.2.187 .

Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet. 2010;375(9713):481–9. https://doi.org/10.1016/s0140-6736(09)61969-3 .

Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29(1):54–60. https://doi.org/10.1200/JCO.2010.29.3183 .

Jousheghany F, Phelps J, Crook T, Hakkak R. Relationship between level of HbA1C and breast cancer. BBA Clin. 2016;6:45–8. https://doi.org/10.1016/j.bbacli.2016.04.005 .

Boursi B, Giantonio BJ, Lewis JD, Haynes K, Mamtani R, Yang Y-X. Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. Eur J Cancer. 2016;59:90–8. https://doi.org/10.1016/j.ejca.2016.02.018 .

Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30. https://doi.org/10.1007/s10549-007-9556-1 .

Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. New York: Springer; 2010.

Frederick LG, Page DL, Fleming ID, et al. AJCC cancer staging manual. New York: Springer; 2013.

Glycemic targets. Diabetes care. 2017;40 (Suppl 1):S48–S56. https://doi.org/10.2337/dc17-s009 .

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23(2):207–38. https://doi.org/10.4158/EP161682.CS .

Duan W, Shen X, Lei J, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014;2014:461917. https://doi.org/10.1155/2014/461917 .

Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014;38(5):330–6. https://doi.org/10.4093/dmj.2014.38.5.330 .

Luo J, Hendryx M, Virnig B, et al. Pre-existing diabetes and breast cancer prognosis among elderly women. Br J Cancer. 2015;113(5):827–32. https://doi.org/10.1038/bjc.2015.249 .

Xu H, Chen K, Jia X, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist. 2015;20(11):1236–44. https://doi.org/10.1634/theoncologist.2015-0096 .

Kim HJ, Kwon H, Lee JW, et al. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res BCR. 2015;17:64. https://doi.org/10.1186/s13058-015-0574-3 .

Peeters PJ, Bazelier MT, Leufkens HG, et al. Insulin glargine use and breast cancer risk: associations with cumulative exposure. Acta oncologica (Stockholm, Sweden). 2016;55(7):851–858. https://doi.org/10.3109/0284186x.2016.1155736 .

Bronsveld HK, ter Braak B, Karlstad O, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res BCR. 2015;17:100. https://doi.org/10.1186/s13058-015-0611-2 .

Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf. 2015;24(1):75–85. https://doi.org/10.1002/pds.3660 .